CW-3308 is an orally effective PROTAC that selectively targets BRD9 and is expected to be used to inhibit synovial sarcoma, rhabdomyoma, and other BRD9-dependent human diseases. CW-3308 is composed of PROTAC target protein ligand Naphthyridin-Me-dimethoxybenzene-COOH (HY-159596) (red part), Linker 3-Azaspiro[5.5]undecane-9-methanol (HY-159598) (black part), E3 ubiquitin ligase ligand Thalidomide-methylpyrrolidine (HY-159597) (blue part), where the conjugate of E3 ubiquitin ligase ligand + linker is Thalidomide-pyrrolidine-C-azaspiro (HY-159599)[1].
Molecular Weight:
800.90
Purity:
97.08
CAS Number:
[3055592-99-6]
Formula:
C45H48N6O8
Target:
Epigenetic Reader Domain,PROTACs
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
